Advice

Following a resubmission

bortezomib (Velcade®) is not recommended for use within NHS Scotland as mono-therapy for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.

Bortezomib, compared to high dose dexamethasone, prolonged time to disease progression by 2.7 months and improved survival in patients who had progressive multiple myeloma despite previous treatment with one to three lines of therapy. However, the manufacturer’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC and they did not present a sufficiently robust economic analysis.

Download detailed advice56KB (PDF)

Download

Medicine details

Medicine name:
bortezomib, 3.5mg vial of powder for solution for intravenous injection (Velcade)
SMC ID:
302/06
Indication:
Multiple myeloma
Pharmaceutical company
Ortho Biotech
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Not recommended
Date advice published:
13 August 2007